Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vonafexor in Impaired Renal Function and Suspected MASH
2023-509192-16-00Phase 2Completed
- Sponsor
- ENYO Pharma
- Start
- Mar 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-arm trial of vonafexor in Renal Insufficiency (RI) and metabolic dysfunction-associated steatohepatitis (MASH), sponsored by ENYO Pharma. Primary endpoint: Change from baseline of mGFRiohexol and eGFRcreat at Week 16. Started Mar 2024; status: completed.
02
Drugs
vonafexor
03
Conditions
Renal Insufficiency (RI)metabolic dysfunction-associated steatohepatitis (MASH)
Beyond the preview
Go deeper on 2023-509192-16-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509192-16-00.